EE03383B1 - Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon - Google Patents

Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon

Info

Publication number: EE03383B1
Authority: EE; Estonia
Prior art keywords: inhibitor; cholesterol; pct; combination; lactam
Prior art date: 1992-12-23

Application number

EE9400341A

Other languages

English (en)

Estonian (et)

Other versions

EE9400341A (et

Inventor

R. Davis Harry

Original Assignee

Schering Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-12-23

Filing date

1994-11-23

Publication date

2001-04-16

1994-11-23 Application filed by Schering Corporation filed Critical Schering Corporation

1996-04-15 Publication of EE9400341A publication Critical patent/EE9400341A/xx

2001-04-16 Publication of EE03383B1 publication Critical patent/EE03383B1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cosmetics (AREA)

EE9400341A 1992-12-23 1994-11-23 Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon EE03383B1 (et)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US99548892A	1992-12-23	1992-12-23

Publications (2)

Publication Number	Publication Date
EE9400341A EE9400341A (et)	1996-04-15
EE03383B1 true EE03383B1 (et)	2001-04-16

Family

ID=25541876

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EE9400341A EE03383B1 (et)	1992-12-23	1994-11-23	Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon

Country Status (32)

Country	Link
US (1)	US5661145A (zh)
EP (1)	EP0675714B1 (zh)
JP (1)	JP3992728B2 (zh)
KR (1)	KR100306936B1 (zh)
CN (1)	CN1090479C (zh)
AT (1)	ATE175872T1 (zh)
AU (1)	AU680864B2 (zh)
CA (1)	CA2152351C (zh)
CZ (1)	CZ287125B6 (zh)
DE (1)	DE69323213T2 (zh)
DK (1)	DK0675714T3 (zh)
EE (1)	EE03383B1 (zh)
ES (1)	ES2128552T3 (zh)
FI (1)	FI952916A (zh)
GR (1)	GR3029405T3 (zh)
HR (1)	HRP931515B1 (zh)
HU (1)	HU221724B1 (zh)
IL (1)	IL108112A (zh)
LT (1)	LT3300B (zh)
LV (1)	LV10919B (zh)
MX (1)	MX9308053A (zh)
MY (1)	MY109538A (zh)
NO (1)	NO311325B1 (zh)
NZ (1)	NZ259790A (zh)
PL (1)	PL174128B1 (zh)
SG (1)	SG45147A1 (zh)
SI (1)	SI9300677A (zh)
SK (1)	SK281173B6 (zh)
TW (1)	TW319698B (zh)
WO (1)	WO1994014433A1 (zh)
YU (1)	YU49060B (zh)
ZA (1)	ZA939552B (zh)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5631365A (en)	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1996009827A2 (en) *	1994-09-20	1996-04-04	Pfizer Inc.	Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US5624920A (en) *	1994-11-18	1997-04-29	Schering Corporation	Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) *	1994-11-18	1997-05-27	Schering Corporation	Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) *	1994-12-21	1997-08-12	Schering Corporation	4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
EA000514B1 (ru)	1995-11-02	1999-10-28	Варнер-Ламберт Компани	Способ нормализации липопротеидного профиля плазмы крови у млекопитающего и фармацевтическая композиция для его осуществления
US20030153541A1 (en) *	1997-10-31	2003-08-14	Robert Dudley	Novel anticholesterol compositions and method for using same
SI20109A (sl) *	1998-12-16	2000-06-30	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Stabilna farmacevtska formulacija
AR023463A1 (es) *	1999-04-16	2002-09-04	Schering Corp	Uso de compuestos de azetidinona
JP4945876B2 (ja) *	2000-04-05	2012-06-06	東レ株式会社	ハイモビリティーグループタンパクの吸着材および体液浄化カラム
US6979462B1 (en) *	2000-10-03	2005-12-27	Mutual Pharmaceutical Co., Inc.	Stabilization of solid drug formulations
US6584357B1 (en) *	2000-10-17	2003-06-24	Sony Corporation	Method and system for forming an acoustic signal from neural timing difference data
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1911462A3 (en)	2001-01-26	2011-11-30	Schering Corporation	Compositions comprising a sterol absorption inhibitor
CN101297969B (zh) *	2001-01-26	2011-03-09	先灵公司	过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药
IL157552A0 (en)	2001-03-28	2004-03-28	Schering Corp	Enantioselective synthesis of azetidinone intermediate compounds
MXPA04002572A (es) *	2001-09-21	2004-05-31	Schering Corp	Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol.
WO2003026643A2 (en) *	2001-09-21	2003-04-03	Schering Corporation	Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US6984645B2 (en)	2001-11-16	2006-01-10	Bristol-Myers Squibb Company	Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20030204096A1 (en) *	2002-03-25	2003-10-30	Schering Corporation	Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en)	2002-07-05	2002-08-14	Astrazeneca Ab	Chemical compounds
US7135556B2 (en) *	2002-07-19	2006-11-14	Schering Corporation	NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es)	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
ES2350977T3 (es)	2002-11-05	2011-01-28	Glaxo Group Limited	Agentes antibacterianos.
MXPA05009503A (es)	2003-03-07	2005-10-18	Schering Corp	Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
DE602004018617D1 (de)	2003-03-07	2009-02-05	Schering Corp	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
EP1606287B1 (en) *	2003-03-07	2013-10-02	Merck Sharp & Dohme Corp.	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
EP1810971B1 (en) *	2003-03-07	2013-12-25	Merck Sharp & Dohme Corp.	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP2005015434A (ja) *	2003-06-27	2005-01-20	Kotobuki Seiyaku Kk	血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
US20060089374A1 (en) *	2003-07-17	2006-04-27	Glenn Cornett	Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
US20050113314A1 (en) *	2003-08-29	2005-05-26	Fong Benson M.	Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
US7371759B2 (en)	2003-09-25	2008-05-13	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
EP1918000A2 (en)	2003-11-05	2008-05-07	Schering Corporation	Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7420059B2 (en)	2003-11-20	2008-09-02	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
JP2007516287A (ja) *	2003-12-23	2007-06-21	メルク　エンド　カムパニー　インコーポレーテッド	抗高コレステロール血症化合物
CA2550215A1 (en)	2003-12-23	2005-07-07	Astrazeneca Ab	Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
GB0329778D0 (en) *	2003-12-23	2004-01-28	Astrazeneca Ab	Chemical compounds
CA2553769C (en) *	2004-01-16	2011-01-04	Merck & Co., Inc.	Npc1l1 (npc3) and methods of identifying ligands thereof
CN101006074B (zh) *	2004-07-01	2012-02-15	欧科生医股份有限公司	作为nk1拮抗剂的哌啶衍生物
US7572805B2 (en)	2004-07-14	2009-08-11	Bristol-Myers Squibb Company	Pyrrolo(oxo)isoquinolines as 5HT ligands
US20060046996A1 (en)	2004-08-31	2006-03-02	Kowa Co., Ltd.	Method for treating hyperlipidemia
US20060154959A1 (en) *	2005-01-13	2006-07-13	Navitas Pharma	Combination therapies of cicletanine and carvedilol
JP2008514718A (ja) *	2004-09-29	2008-05-08	シェーリングコーポレイション	置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
US7517991B2 (en)	2004-10-12	2009-04-14	Bristol-Myers Squibb Company	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076598A2 (en)	2005-01-12	2006-07-20	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (en)	2005-01-12	2006-07-20	Bristol-Myers Squibb Company	Thiazolopyridines as cannabinoid receptor modulators
WO2006076597A1 (en)	2005-01-12	2006-07-20	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid receptor modulators
US20080096915A1 (en) *	2005-01-13	2008-04-24	Greenberg Traurig LLP	Compositions for the treatment of metabolic disorders
US20070141174A1 (en) *	2005-01-13	2007-06-21	Navitas Pharma, Inc.	Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20060160850A1 (en)	2005-01-18	2006-07-20	Chongqing Sun	Bicyclic heterocycles as cannabinoid receptor modulators
DE602006004964D1 (de)	2005-02-10	2009-03-12	Bristol Myers Squibb Co	Dihydrochinazolinone als 5ht-modulatoren
US7629342B2 (en)	2005-06-17	2009-12-08	Bristol-Myers Squibb Company	Azabicyclic heterocycles as cannabinoid receptor modulators
US7317012B2 (en)	2005-06-17	2008-01-08	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7572808B2 (en)	2005-06-17	2009-08-11	Bristol-Myers Squibb Company	Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en)	2005-06-17	2009-12-15	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7452892B2 (en)	2005-06-17	2008-11-18	Bristol-Myers Squibb Company	Triazolopyrimidine cannabinoid receptor 1 antagonists
UY29607A1 (es) *	2005-06-20	2007-01-31	Astrazeneca Ab	Compuestos quimicos
JP2008546784A (ja) *	2005-06-20	2008-12-25	シェーリングコーポレイション	ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体
AR054482A1 (es) *	2005-06-22	2007-06-27	Astrazeneca Ab	Derivados de azetidinona para el tratamiento de hiperlipidemias
MY148538A (en) *	2005-06-22	2013-04-30	Astrazeneca Ab	Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AR057383A1 (es) *	2005-06-22	2007-12-05	Astrazeneca Ab	Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar)	2005-06-22	2010-03-29	استرازينيكا ايه بي	مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057380A1 (es) *	2005-06-22	2007-11-28	Astrazeneca Ab	Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
US7795436B2 (en)	2005-08-24	2010-09-14	Bristol-Myers Squibb Company	Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AR056155A1 (es)	2005-10-26	2007-09-19	Bristol Myers Squibb Co	Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US20070105817A1 (en) *	2005-11-09	2007-05-10	Jim Page	Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
WO2007075702A2 (en) *	2005-12-21	2007-07-05	Schering Corporation	Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
US7553836B2 (en)	2006-02-06	2009-06-30	Bristol-Myers Squibb Company	Melanin concentrating hormone receptor-1 antagonists
WO2007100807A2 (en)	2006-02-24	2007-09-07	Schering Corporation	Npc1l1 orthologues
TW200811098A (en)	2006-04-27	2008-03-01	Astrazeneca Ab	Chemical compounds
US20070275052A1 (en) *	2006-05-24	2007-11-29	Glenmark Pharmaceuticals Limited	Pharmaceutical compositions containing sterol inhibitors
US20080103122A1 (en) *	2006-09-05	2008-05-01	Schering Corporation	Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20080312241A1 (en) *	2007-01-03	2008-12-18	Gilead Sciences, Inc.	Cicletanine and PKC inhibitors in the treatment of pulmonary and cardiac disorders
US20090011994A1 (en)	2007-07-06	2009-01-08	Bristol-Myers Squibb Company	Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es)	2008-05-29	2009-12-31	Bristol Myers Squibb Co	Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2010021681A2 (en) *	2008-08-18	2010-02-25	Combinatorx (Singapore) Pte. Ltd.	Compositions and methods for treatment of viral diseases
EP2411005A1 (en)	2009-03-27	2012-02-01	Bristol-Myers Squibb Company	Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
EP2892897A1 (en)	2012-09-05	2015-07-15	Bristol-Myers Squibb Company	Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
EP2892896B1 (en)	2012-09-05	2016-06-29	Bristol-Myers Squibb Company	Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
KR20210034039A (ko)	2018-07-19	2021-03-29	아스트라제네카 아베	다파글리플로진을 사용하는 HFpEF의 치료 방법 및 이를 포함하는 조성물
IL308122A (en)	2021-06-16	2023-12-01	Celgene Corp	Azetidinyl compounds consisting of a carboxylic acid group for the treatment of neurodegenerative diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4680391A (en) *	1983-12-01	1987-07-14	Merck & Co., Inc.	Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4983597A (en) *	1989-08-31	1991-01-08	Merck & Co., Inc.	Beta-lactams as anticholesterolemic agents
US5120729A (en) *	1990-06-20	1992-06-09	Merck & Co., Inc.	Beta-lactams as antihypercholesterolemics
US5085473A (en) *	1990-10-09	1992-02-04	Yuhe Yang	Air actuated car curtain device
TW223059B (zh) *	1991-07-23	1994-05-01	Schering Corp
ES2613245T3 (es)	2012-01-26	2017-05-23	Intralot S.A. - Integrated Lottery Systems And Services	Métodos y sistemas para dispensar

1993
- 1993-12-03 LT LTIP1514A patent/LT3300B/lt not_active IP Right Cessation
- 1993-12-13 MX MX9308053A patent/MX9308053A/es unknown
- 1993-12-21 EP EP94904854A patent/EP0675714B1/en not_active Expired - Lifetime
- 1993-12-21 AT AT94904854T patent/ATE175872T1/de active
- 1993-12-21 CA CA002152351A patent/CA2152351C/en not_active Expired - Fee Related
- 1993-12-21 KR KR1019950702608A patent/KR100306936B1/ko not_active IP Right Cessation
- 1993-12-21 AU AU58720/94A patent/AU680864B2/en not_active Ceased
- 1993-12-21 DK DK94904854T patent/DK0675714T3/da active
- 1993-12-21 IL IL10811293A patent/IL108112A/en not_active IP Right Cessation
- 1993-12-21 NZ NZ259790A patent/NZ259790A/en not_active IP Right Cessation
- 1993-12-21 TW TW082110824A patent/TW319698B/zh not_active IP Right Cessation
- 1993-12-21 SK SK783-95A patent/SK281173B6/sk not_active IP Right Cessation
- 1993-12-21 WO PCT/US1993/012291 patent/WO1994014433A1/en active IP Right Grant
- 1993-12-21 PL PL93309636A patent/PL174128B1/pl not_active IP Right Cessation
- 1993-12-21 ES ES94904854T patent/ES2128552T3/es not_active Expired - Lifetime
- 1993-12-21 DE DE69323213T patent/DE69323213T2/de not_active Expired - Lifetime
- 1993-12-21 YU YU80293A patent/YU49060B/sh unknown
- 1993-12-21 CZ CZ19951643A patent/CZ287125B6/cs not_active IP Right Cessation
- 1993-12-21 MY MYPI93002792A patent/MY109538A/en unknown
- 1993-12-21 HU HU9501854A patent/HU221724B1/hu not_active IP Right Cessation
- 1993-12-21 ZA ZA939552A patent/ZA939552B/xx unknown
- 1993-12-21 US US08/454,348 patent/US5661145A/en not_active Expired - Lifetime
- 1993-12-21 SG SG1996000543A patent/SG45147A1/en unknown
- 1993-12-21 JP JP51530594A patent/JP3992728B2/ja not_active Expired - Fee Related
- 1993-12-22 SI SI9300677A patent/SI9300677A/sl not_active IP Right Cessation
- 1993-12-22 HR HR07/995,488A patent/HRP931515B1/xx not_active IP Right Cessation
- 1993-12-22 CN CN93112663A patent/CN1090479C/zh not_active Expired - Fee Related
1994
- 1994-11-23 EE EE9400341A patent/EE03383B1/xx not_active IP Right Cessation
1995
- 1995-06-14 FI FI952916A patent/FI952916A/fi unknown
- 1995-06-22 LV LVP-95-189A patent/LV10919B/en unknown
- 1995-06-23 NO NO19952529A patent/NO311325B1/no not_active IP Right Cessation
1999
- 1999-02-16 GR GR990400487T patent/GR3029405T3/el unknown

Also Published As

Publication number	Publication date
IL108112A0 (en)	1994-04-12
CN1095591A (zh)	1994-11-30
AU5872094A (en)	1994-07-19
CN1090479C (zh)	2002-09-11
CZ287125B6 (en)	2000-09-13
CZ164395A3 (en)	1996-03-13
SK78395A3 (en)	1996-05-08
SK281173B6 (sk)	2000-12-11
WO1994014433A1 (en)	1994-07-07
PL309636A1 (en)	1995-10-30
HU9501854D0 (en)	1995-08-28
CA2152351C (en)	2009-09-22
JP3992728B2 (ja)	2007-10-17
SG45147A1 (en)	1998-01-16
DK0675714T3 (da)	1999-09-13
HRP931515B1 (en)	2000-02-29
NZ259790A (en)	1997-02-24
LV10919B (en)	1996-04-20
LT3300B (en)	1995-06-26
EP0675714B1 (en)	1999-01-20
EP0675714A1 (en)	1995-10-11
HRP931515A2 (en)	1996-12-31
ZA939552B (en)	1994-10-12
YU80293A (sh)	1997-12-05
US5661145A (en)	1997-08-26
LTIP1514A (en)	1994-10-25
NO952529L (no)	1995-06-23
CA2152351A1 (en)	1994-07-07
FI952916A0 (fi)	1995-06-14
NO952529D0 (no)	1995-06-23
DE69323213D1 (de)	1999-03-04
KR100306936B1 (ko)	2001-11-30
MX9308053A (es)	1994-06-30
ATE175872T1 (de)	1999-02-15
YU49060B (sh)	2003-08-29
NO311325B1 (no)	2001-11-19
PL174128B1 (pl)	1998-06-30
HUT72081A (en)	1996-03-28
GR3029405T3 (en)	1999-05-28
JPH08505141A (ja)	1996-06-04
IL108112A (en)	1999-11-30
AU680864B2 (en)	1997-08-14
EE9400341A (et)	1996-04-15
ES2128552T3 (es)	1999-05-16
MY109538A (en)	1997-02-28
DE69323213T2 (de)	1999-07-08
HU221724B1 (hu)	2002-12-28
FI952916A (fi)	1995-06-14
TW319698B (zh)	1997-11-11
LV10919A (lv)	1995-12-20
SI9300677A (en)	1994-09-30

Publication	Publication Date	Title
EE03383B1 (et)	2001-04-16	Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon
GEP20033006B (en)	2003-07-10	Sugar-Substituted 2-Azetidinones Useful as Hypocholesterolemic Agents
AU7321598A (en)	1998-09-22	Use of cholinesterase inhibitors to treat disorders of attention
BG103190A (en)	1999-11-30	Substituted pyrimidine derivatives and their pharmaceutical application
AU2483000A (en)	2000-07-24	Treatment of asthma with mek inhibitors
DE69831937D1 (de)	2006-03-02	Bicyclische protein-farnesyl-transferase inhibitoren
AU3451797A (en)	1998-02-02	Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
EP0646007A4 (zh)	1995-04-26
ATE229331T1 (de)	2002-12-15	Inhibitoren von metazoan-parasit-proteasen
AU9066498A (en)	1999-02-16	Substituted 6-alkylphenanthridines
MD960168A (ro)	1998-04-30	Metodă şi compuşi pentru tratamentul infecţiilor virale
AU2961199A (en)	1999-10-25	Hiv cofactor inhibitors and medicinal compositions for preventing or treating hiv-infection
HUT73231A (en)	1996-07-29	Pharmaceutical compositions with 17-beta-monosubstituted-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones for treatment of chronic prostatitis
ATE316385T1 (de)	2006-02-15	Zusammensetzungen zur behandlung und vorbeugung von atherosklerose
PT912568E (pt)	2003-04-30	Imidazopiridinas
AU5625194A (en)	1994-06-22	Rectal flunisolide compositions for treating inflammatory intestinal disorders
UA41376C2 (uk)	2001-09-17	ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ АНДРОГЕННОЇ АЛОПЕЦІЇ ІНГІБІТОРАМИ 5-<font face="Symbol">a</font>-РЕДУКТАЗИ

Legal Events

Date	Code	Title	Description
2003-02-17	KB4A	Valid patent at the end of a year	Effective date: 20021231
2004-02-16	KB4A	Valid patent at the end of a year	Effective date: 20031231
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2006-02-15	KB4A	Valid patent at the end of a year	Effective date: 20051231
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	KB4A	Valid patent at the end of a year	Effective date: 20071231
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2010-02-15	KB4A	Valid patent at the end of a year	Effective date: 20091231
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231
2012-08-15	MM4A	Lapsed by not paying the annual fees	Effective date: 20111123